Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 8152610, 4 pages
https://doi.org/10.1155/2017/8152610
Case Report

Cutaneous Vasculitis: An Unusual Presentation of a Biclonal Nodal Plasma Cell Dyscrasia

1Haematology Department, University Hospital Waterford, Regional Cancer Center South East, University College Cork, Cork, Ireland
2Pathology Department, University Hospital Waterford, Regional Cancer Center South East, University College Cork, Cork, Ireland

Correspondence should be addressed to D. Swan; moc.liamg@321nawsnwad

Received 27 June 2017; Accepted 31 July 2017; Published 13 September 2017

Academic Editor: Marie-Christine Kyrtsonis

Copyright © 2017 D. Swan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Pratt, M. Jenner, R. Owen et al., “Updates to the guidelines for the diagnosis and management of multiple myeloma,” British Journal of Haematology, vol. 167, no. 1, pp. 131–133, 2014. View at Publisher · View at Google Scholar
  2. J. Loricera, V. Calvo-Río, F. Ortiz-Sanjuán et al., “The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features,” Medicine (United States), vol. 92, no. 6, pp. 331–343, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Kyle, R. A. Robinson, and J. A. Katzmann, “The clinical aspects of biclonal gammopathies. Review of 57 cases,” The American Journal of Medicine, vol. 71, no. 6, pp. 999–1008, 1981. View at Publisher · View at Google Scholar · View at Scopus
  4. T. C. Mullikin, S. V. Rajkumar, A. Dispenzieri et al., “Clinical characteristics and outcomes in biclonal gammopathies,” American Journal of Hematology, vol. 91, no. 5, pp. 473–475, 2016. View at Publisher · View at Google Scholar
  5. Z. W. Chen, I. Kotsikogianni, J. S. Raval, C. G. Roth, and M. A. Rollins-Raval, “Biclonal IgD and IgM plasma cell myeloma: a report of two cases and a literature review,” Case Reports in Hematology, vol. 2013, Article ID 293150, pp. 1–5, 2013. View at Publisher · View at Google Scholar
  6. B. T.-Y. Lin and L. M. Weiss, “Primary plasmacytoma of lymph nodes,” Human Pathology, vol. 28, no. 9, pp. 1083–1090, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Varettoni, A. Corso, G. Pica, S. Mangiacavalli, C. Pascutto, and M. Lazzarino, “Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients,” Annals of Oncology, vol. 21, no. 2, pp. 325–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Z. Usmani, C. Heuck, A. Mitchell et al., “Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents,” Haematologica, vol. 97, no. 11, pp. 1761–1767, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Rosiñol, M. T. Cibeira, C. Uriburu et al., “Bortezomib: an effective agent in extramedullary disease in multiple myeloma,” European Journal of Haematology, vol. 76, no. 5, pp. 405–408, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Fukushima, T. Nakamura, M. Miki et al., “Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas,” Anticancer Research, vol. 30, no. 9, pp. 3791–3794, 2010. View at Google Scholar · View at Scopus
  11. S. D'Sa, N. Abildgaard, J. Tighe, P. Shaw, and M. Hall-Craggs, “Guidelines for the use of imaging in the management of myeloma,” British Journal of Haematology, vol. 137, no. 1, pp. 49–63, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Cavo, E. Terpos, C. Nanni et al., “Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group,” The Lancet Oncology, vol. 18, no. 4, pp. e206–e217, 2017. View at Publisher · View at Google Scholar
  13. Y.-Y. Lu, J.-H. Chen, W.-Y. Lin et al., “FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis,” Clinical Nuclear Medicine, vol. 37, no. 9, pp. 833–837, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. E. Mulligan and A. Z. Badros, “PET/CT and MR imaging in myeloma,” Skeletal Radiology, vol. 36, no. 1, pp. 5–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Nanni, E. Zamagni, A. Versari et al., “Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe),” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 3, pp. 414–421, 2016. View at Publisher · View at Google Scholar · View at Scopus